Non small cell lung cancer, Poor general status research hub

IFCT-1802 SAVIMMUNE A phase II single-arm trial evaluating safety and efficacy of Durvalumab in ECOG Performance Status 2-3, treatment-naive, patients with stage IV Non-Small Cell Lung Cancer (NSCLC) and high PD-L1 tumor expression

This study looks at a new cancer treatment called durvalumab (Imfinzi) for people with a type of advanced lung cancer. It aims to see how safe the treatment is and if it helps people feel better. It focuses on patients who are quite unwell at the start.